|
|
Article: Encouraging data for Neurocrine's indiplon.(Neurocrine Biosciences)(Brief Article)
- Article from:
- Pharma Marketletter
- Article date:
- February 21, 2005
CopyrightCOPYRIGHT 2005 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences of the USA says that its indiplon MR 15mg tablets showed a statistically-significant improvement for all primary and secondary endpoints in the firm's Phase III clinical trial involving 248 adult patients with chronic insomnia.
Efficacy results with the agent demonstrated a highly statistically-significant and clinically-relevant improvement on the primary endpoint of patient-reported total sleep time versus placebo (p=0.0002), the company noted. Patients receiving indiplon gained approximately one hour of sleep over baseline. Safety results were consistent with those previously reported in other Phase III indiplon studies.
"These ...